2022
Holistic management of hepatocellular carcinoma: The hepatologist's comprehensive playbook
Jaffe A, Taddei TH, Giannini EG, Ilagan‐Ying Y, Colombo M, Strazzabosco M. Holistic management of hepatocellular carcinoma: The hepatologist's comprehensive playbook. Liver International 2022, 42: 2607-2619. PMID: 36161463, PMCID: PMC10878125, DOI: 10.1111/liv.15432.Peer-Reviewed Original ResearchConceptsLiver diseaseHepatocellular carcinomaLiver functionRisk factorsRelevant prognostic roleChronic hepatitis BResidual liver functionChronic liver diseaseManagement of patientsCare of patientsCommon risk factorsAppropriate surveillance strategiesSuccessful cancer treatmentC infectionCommon complicationHepatitis BMetabolic syndromePrognostic roleSignificant morbidityLongitudinal careCurrent careCancer recurrenceHCC managementLiver cancerHCC treatment
2021
Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation
Torgersen J, Newcomb CW, Carbonari DM, Rentsch CT, Park LS, Mezochow A, Mehta RL, Buchwalder L, Tate JP, Bräu N, Bhattacharya D, Lim JK, Taddei TH, Justice AC, Lo Re V. Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation. Journal Of Hepatology 2021, 75: 1312-1322. PMID: 34333102, PMCID: PMC8604762, DOI: 10.1016/j.jhep.2021.07.021.Peer-Reviewed Original ResearchConceptsSevere hepatic dysfunctionBaseline FIB-4Acute liver injuryHepatic dysfunctionInhibitor-based treatmentHepatic decompensationFIB-4Liver injuryHigh riskDAA therapyHazard ratioAdvanced liver fibrosis/cirrhosisRisk of ALIProtease inhibitor-based regimensProtease inhibitor-based treatmentLiver fibrosis/cirrhosisInhibitor-based regimensHepatitis C infectionSevere liver dysfunctionFibrosis/cirrhosisInhibitor-based therapyAminotransferase elevationChronic HCVALT elevationC infection
2020
Liver Pathologic Changes After Direct-Acting Antiviral Agent Therapy and Sustained Virologic Response in the Setting of Chronic Hepatitis C Virus Infection.
Celli R, Saffo S, Kamili S, Wiese N, Hayden T, Taddei T, Jain D. Liver Pathologic Changes After Direct-Acting Antiviral Agent Therapy and Sustained Virologic Response in the Setting of Chronic Hepatitis C Virus Infection. Archives Of Pathology & Laboratory Medicine 2020, 145: 419-427. PMID: 32810870, PMCID: PMC10960369, DOI: 10.5858/arpa.2020-0008-oa.Peer-Reviewed Original ResearchConceptsHepatocellular carcinomaHCC developmentChronic hepatitis C virus (HCV) infectionChronic viral hepatitis C infectionHepatitis C virus infectionViral hepatitis C infectionTissue polymerase chain reactionAntiviral agent therapyLiver histologic findingsLiver pathologic changesNon-SVR groupOccult HCV infectionPersistent liver inflammationSuccessful DAA therapyC virus infectionHepatitis C infectionSubset of patientsDegree of inflammationNumber of patientsPresence of virusDAA therapySVR patientsVirologic responseC infectionHCV infectionExcess Weight Gain After Cure of Hepatitis C Infection with Direct-Acting Antivirals
Do A, Esserman DA, Krishnan S, Lim JK, Taddei TH, Hauser RG, Tate JP, Re VL, Justice AC. Excess Weight Gain After Cure of Hepatitis C Infection with Direct-Acting Antivirals. Journal Of General Internal Medicine 2020, 35: 2025-2034. PMID: 32342483, PMCID: PMC7352003, DOI: 10.1007/s11606-020-05782-6.Peer-Reviewed Original ResearchConceptsDAA treatmentExcess weight gainTreatment initiationWeight gainChronic hepatitis C virus (HCV) infectionHigh FIB-4 scoreHepatitis C virus infectionC virus infectionFIB-4 scoreHepatitis C infectionDirect acting antiviralsLiver disease progressionMultiple logistic regressionConclusionWeight gainDAA therapySVR achievementC infectionBaseline weightProspective studyExcess weightDisease progressionVirus infectionHigh riskPatientsBirth cohort
2019
Macrotrabecular Hepatocellular Carcinoma
Jeon Y, Benedict M, Taddei T, Jain D, Zhang X. Macrotrabecular Hepatocellular Carcinoma. The American Journal Of Surgical Pathology 2019, 43: 943-948. PMID: 31135484, DOI: 10.1097/pas.0000000000001289.Peer-Reviewed Original ResearchMeSH KeywordsAgedAlpha-FetoproteinsCarcinoma, HepatocellularDisease ProgressionFemaleHepatectomyHepatitis BHepatitis CHumansLiver CirrhosisLiver NeoplasmsLiver TransplantationMaleMiddle AgedNeoplasm GradingNeoplasm Recurrence, LocalNeoplasm StagingProgression-Free SurvivalRetrospective StudiesRisk FactorsTime FactorsTumor BurdenConceptsHepatocellular carcinomaHCC subtypesHigh alpha-fetoprotein levelsWorse recurrence-free survivalDistinct HCC subtypeHepatitis C infectionRecurrence-free survivalAlpha-fetoprotein levelsAnaplastic tumor cellsHigh histologic gradePoor overall survivalConventional hepatocellular carcinomaHigh recurrence rateHigher AJCC stageDetailed pathologic evaluationMacrotrabecular patternC infectionPrimary resectionHepatitis BOverall survivalPathologic evaluationAJCC stageClinicopathologic featuresHistologic subtypeRecurrence rate